scPharmaceuticals Inc. financial data

Symbol
SCPH on Nasdaq
Location
25 Burlington Mall Road, Suite 203, Burlington, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 594 % -12.9%
Quick Ratio 90.8 % +9.66%
Debt-to-equity 2.2K % +1077%
Return On Equity -2.09K % -934%
Return On Assets -90.9 % -29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.3M shares +6.54%
Common Stock, Shares, Outstanding 53.3M shares +47.5%
Entity Public Float 274M USD +263%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 53.7M shares +37.8%
Weighted Average Number of Shares Outstanding, Diluted 53.7M shares +37.8%

Income Statement

Label TTM Value / Value Unit Change %
Cost of Revenue 15.8M USD +127%
Research and Development Expense 15.4M USD +26.8%
Operating Income (Loss) -66.5M USD -10.2%
Net Income (Loss) Attributable to Parent -91.7M USD -51.2%
Earnings Per Share, Basic -1 USD/shares -16.7%
Earnings Per Share, Diluted -1 USD/shares -16.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 40.8M USD +5.99%
Accounts Receivable, after Allowance for Credit Loss, Current 19.4M USD +217%
Inventory, Net 14.6M USD -4.8%
Assets, Current 78.7M USD +25.7%
Property, Plant and Equipment, Net 48K USD +2.13%
Operating Lease, Right-of-Use Asset 1.18M USD -10.2%
Assets 80.3M USD +22.6%
Accounts Payable, Current 4.03M USD -24%
Employee-related Liabilities, Current 4.14M USD +29.5%
Accrued Liabilities, Current 16.1M USD +117%
Liabilities, Current 20.4M USD +58%
Operating Lease, Liability, Noncurrent 984K USD -16.9%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 102M USD +80.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -404M USD -29.3%
Stockholders' Equity Attributable to Parent -21.3M USD -330%
Liabilities and Equity 80.3M USD +22.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -17.1M USD +3.18%
Net Cash Provided by (Used in) Financing Activities -972K USD
Net Cash Provided by (Used in) Investing Activities 29.3M USD +319%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 53.3M shares +47.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.1M USD -256%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 40.8M USD +5.99%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.39M USD -5.72%
Deferred Tax Assets, Valuation Allowance 94.1M USD +28.6%
Deferred Tax Assets, Gross 94.4M USD +27%
Operating Lease, Liability 1.25M USD -9.17%
Depreciation 17K USD -26.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -91.7M USD -51.3%
Lessee, Operating Lease, Liability, to be Paid 1.57M USD -14.7%
Property, Plant and Equipment, Gross 136K USD +14.3%
Operating Lease, Liability, Current 264K USD +38.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 367K USD +5.16%
Lessee, Operating Lease, Liability, to be Paid, Year One 384K USD +12.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 317K USD -31.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 369K USD +3.07%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 1.38M USD +11.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 249K USD -32.2%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 5.33M USD -5.38%
Interest Expense 6.12M USD -27%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%